TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.

Barbara H McGovern et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.